Introduction 3,4-methylenedioxypyrovalerone (MDPV), 4-methyl-N-methylcathinone (mephedrone), N-benzylpiperazine (BZP) and 1-[3-(trifluoromethyl)phenyl]piperazine (TFMPP) are four of the many designer compounds that have been temporarily or permanently placed on the United States Drug Enforcement Administration (DEA) Controlled Substance Act (CSA) (1, 2) . Chemical structures of these compounds are shown in Figure 1 . MDPV and mephedrone belong to the class of synthetic cathinones (3), whereas BZP and TFMPP are piperazine derivatives (4) . Although in different chemical classes, these four compounds are abused worldwide for their amphetaminelike or hallucinogenic properties (5 -7). However, the legal status of each compound is not consistent from country to country (8) . These compounds have no current medical use, nor were they under investigation for new drug applications upon their placement into Schedule I of the United States CSA. Designer drugs pose an imminent hazard to public safety due to a fairly recent increase in their abuse, which has occurred because of their psychoactive effects (9, 10) . The recreational use of these compounds has resulted in emergency room visits and interaction with law enforcement, and has played a role in users' deaths (11, 12) .
These compounds and similar designer analogs are encountered on a routine basis in forensic laboratories as seized drug samples, in Driving Under the Influence (DUI) cases and in postmortem samples. Until recently, they were readily obtainable from head shops and gas stations, and are currently readily available via the internet (13) . Difficulties in the analysis of these compounds arise from the numerous analogs available to users, many of which are not specifically listed in the legislation banning these drugs (14) . In addition to the legal problems these analogs pose during an investigation, reference material for all analogs may not be available in every laboratory for proper reference matching. Further complications may arise with the storage of biological samples from DUI and postmortem cases because the storage conditions may affect the analytical results obtained for these compounds. The stability of MDPV, mephedrone, BZP and TFMPP, when stored at refrigerator temperatures in biological specimens, has been a concern in the authors' laboratory since these compounds were first encountered. It was this concern that provided the impetus for this research. Compounds from each class were included so that relative stabilities for each may be determined.
Materials and Methods

Chemicals and solutions
All aqueous solutions were prepared using deionized (DI) water, which was obtained using a mixed-mode deionizing unit (US Filter Inc., Arlington, TX). All chemicals were purchased in the highest possible purity and used without any further purification. Methanolic standards of BZP, TFMPP, MDPV, mephedrone, MDPV-d 3 and mephedrone-d 3 were purchased from Cerilliant (Round Rock, TX). Methanol, acetonitrile, ammonium hydroxide, potassium phosphate, hydrochloric acid and methylene chloride were purchased from Fisher Scientific (Pittsburgh, PA). Formic acid (97%) was purchased from ICN Biomedicals (Irvine, CA).
Two separate 10 mL stock solutions containing each analyte of interest were prepared independently at a concentration of 1.0 mg/mL in methanol. Each of these stock solutions was derived from a unique lot of methanolic 1 mg/mL standard obtained from the manufacturer, or a separate vial if a unique lot was not available. These two stock solutions were subsequently identified as calibrators and controls. MDPV-d 3 and mephedrone-d 3 were used as internal standards for these experiments. The internal standard stock solution was prepared at a concentration of 1.0 mg/mL in 10 mL of methanol from a 100 mg/mL neat standard of each compound. Once prepared, the solutions were transferred to 10 mL amber glass bottles, capped and placed in the freezer for storage at -208C.
The aqueous portion of the high-performance liquid chromatography (HPLC) buffer was 2 mM ammonium formate containing 2% formic acid. The primary organic component of the mobile phase was HPLC-grade acetonitrile with 0.1% formic acid. The ratio of the previous aqueous mixture to acetonitrile with 0.1% formic acid was first set at 95:5. The LC was run in a gradient mode so that the mixture was changed to 5:95 during the first 3 min. This ratio was changed to 95:5 at 3.01 min and was held there until 3.5 min for re-equilibration. The total chromatographic run time was 3.5 min for this analysis.
Instrumentation
Analyte separation was achieved using a Shimadzu Nexera ultrahigh-performance liquid chromatography (UHPLC) system (Shimadzu, Kyoto Japan) equipped with a Security Guard PFP guard column (4.0 Â 3.0 mm i.d., 3 mm particles) from Phenomenex (Torrance, CA), followed immediately by a Phenomenex Kintex PFP analytical column (50 Â 2.1 mm i.d., 1.8 mm particles). Identification and quantitation were accomplished using an ABSciex 4000 QTrap hybrid triple quadrupolelinear ion trap mass spectrometer (ABSciex, Framingham, MA), which utilized nitrogen as the sheath and reagent gas.
Liquid chromatography-tandem mass spectrometry method For all determinations, the HPLC was operated in a gradient mode with a flow rate of 500 mL/min. The sample injection volume was 5 mL. The HPLC column was routinely equilibrated prior to use. Initial ionization evaluation of these compounds by direct injection into the QTrap indicated that positive electrospray ionization (ESI), creating the [M þ H] þ ions, was much more effective in signal production than negative electrospray ionization. ESI-mass spectrometry (MS) conditions were optimized separately for each of the three compounds by infusing the desired compound at a concentration of 1 mg/mL, prepared by dilution from the stock solutions using methanol, into the QTrap at a constant rate of 10 mL/min. Tuning the MS for the desired ions was then accomplished using the autotune feature of the Analyst software. Ions used to quantify and qualify these compounds, in addition to the collision energy, the declustering potential and the exit potential setting are shown in Table I .
Sample extraction
Calibration curves were prepared by dilution utilizing human certified-negative whole blood (UTAK Laboratories, Valencia, CA) as the diluent. Controls were prepared in a similar manner to calibrators, using the same human certifiednegative whole blood as diluent, but employing the second set of original stock solutions. Only whole blood controls were used in these assays. Calibrators, controls and stability specimens, all simply referred to as samples, were prepared and extracted in the following manner. First, 100 mL aliquots of blood, urine or plasma were transferred into 6 mL glass extraction tubes. One milliliter of 100 mM phosphate buffer ( pH 6.00) was added to each tube, followed by 20 mL of the 1 mg/mL internal standard solution and then the tubes were vortexed for 30 s. United Chemical Technologies (UCT, Bristol, PA) CSDAU206 Clean Screen solid-phase extraction (SPE) columns were conditioned in the following manner. One milliliter of methanol was allowed to pass through each column that was placed on a UCT Positive Pressure Manifold, followed by 1 mL of 100 mM phosphate buffer ( pH 6.00). The samples were then added to the SPE extraction columns and allowed to pass through.
Once the entire sample had passed through the column, 1 mL of DI water was applied as the first of three wash steps. Second, 1 mL of 0.10 N hydrochloric acid was added, followed by 1 mL of methanol. Each wash step was allowed to pass through the column prior to the addition of the next step. Following the methanol wash, full positive pressure (.25 psi) was applied to the SPE columns for 5 min. Samples were eluted into collection tubes with a mixture of methylene chlorideisopropyl alcohol-ammonium hydroxide (77:20:3). Samples were allowed to dry under warm air provided by a forced-air drier. After samples were completely dry, they were reconstituted with 200 mL of a 50:50 mixture of 10 mM formate buffer ( pH 3.00) and acetonitrile.
Analyte stability
The stability of the analytes was investigated by monitoring the concentration of specimens prepared in each matrix and stored under various conditions over time. This study was begun by preparing three separate 1,000 ng/mL specimens, each containing all four of the analytes of interest. These specimens were prepared in certified-negative human whole blood, certified-negative human plasma and certified-negative human urine. On Day 1 of the experiment, each specimen type was analyzed to obtain an initial concentration for each of the three matrices. Once the specimens were analyzed, each was divided into three separate glass containers for storage in the freezer (-208C), refrigerator (48C) or at room temperature (228C). Each storage location was dark and each glass container was sealed during storage. Temperatures for the freezer and refrigerator were monitored and logged daily as part of the standard laboratory procedure. The freezer used did not undergo freeze-thaw cycles; however, the frozen specimens for each matrix type were thawed before aliquoting on each analysis day as they would have been if they were authentic case specimens. The room temperature samples were maintained, with slight variation, at 228C, as controlled by the thermostat in the laboratory. On Days 2, 4, 7 and 14, the containers were opened and thawed if necessary, and aliquots were removed for analysis. A new calibration curve was prepared and analyzed on each day of the experiment. The validity of each calibration curve was evaluated using quality control (QC) samples prepared from a different stock solution of analytes. The QCs were prepared on the day of analysis. Three aliquots from each matrix type and each storage temperature were analyzed on each day of the experiment. The average values obtained and the associated standard deviations are reported.
Results and Discussion
Method validation
Quantitation of BZP, TFMPP, MDPV and mephedrone in samples was achieved via an internal standard calibration procedure. Response factors for each compound were determined for each sample. The response factor for each analyte was calculated by dividing the area of the analyte peak by the area of the internal standard peak. The following MS-MS ions: m/z 91.1, 119.1, 126.0 and 160.1, were used for BZP, TFMPP, MDPV and mephedrone quantitation, respectively. The MS-MS ion at m/z 134.0 was used for the internal standard, MDPV-d 8 , and m/z 148.1 was used for mephedrone-d 3 . Mephedrone and MDPV were quantified using their deuterated analogues; BZP and TFMPP were quantified using MDPV-d 8 as the internal standard. Calibration curves were prepared by plotting a linear regression of the analyte/internal standard response factor versus the analyte concentration for the calibrators, and used to determine the concentrations of each analyte in controls and specimens. The chromatographic peaks for each analyte were wellshaped, nearly completely resolved and readily distinguished from noise when analyte levels were near the limit of quantitation (LOQ) for each of the authentic samples. The compounds experienced no interference from endogenous sample matrix components. Typical retention times were 1.25, 2.15, 2.26 and 1.60 min for BZP, TFMPP, MDPV and mephedrone, respectively.
The limit of detection (LOD), LOQ and linear dynamic range (LDR) were determined for each analyte. The LOD was defined as the lowest concentration of analyte having the criteria of a minimum signal-to-noise (S/N) ratio of 5 and +5% retention time. The LOQ was defined as the lowest concentration meeting all LOD criteria plus having an S/N ratio of 10 and a measured value within +20% of its target concentration. The LOD was found to be 1 ng/mL for both BZP and TFMPP and 2 ng/mL for MDPV and mephedrone. The LOQ was found to be 2 ng/mL for both BZP and TFMPP and 5 ng/mL for MDPV and mephedrone. Calibration curves for each of the four compounds were linear within 5 -2,000 ng/mL. The correlation coefficients for each calibration curve exceeded 0.99 when a weighting factor of 1/x was used.
Carryover from one sample to the next was not found to be a problem. It was, however, initially investigated and subsequently monitored by the use of blank solvent injections. A formate buffer -acetonitrile blank initially injected following the highest calibrator showed no carryover contamination. Subsequently, blanks were used throughout the sample sequence to verify that no sample-to-sample contamination occurred.
Ion suppression or enhancement was investigated for each matrix type by infusing a mixture of each compound while simultaneously injecting an extracted drug-negative matrix blank. Under the chromatographic conditions described, there was slight but uniform ion suppression of less than 10% between 1.25 and 2.25 min. This pattern was consistent for each matrix investigated.
Stability
Stability data are shown in Tables II -V. The data were evaluated based on both matrix and storage temperature. Although not typical in a laboratory setting, samples were allowed to sit at room temperature for 14 days to evaluate the stability of these compounds under extreme conditions. As expected, both matrix and storage temperature played significant roles in the stability of these compounds. MDPV data are shown in Table II. MDPV was stable in all three examined matrices when stored at either -20 or 48C for periods of up to 14 days. At 228C, both plasma and urine samples were stable for 14 days. Whole blood showed an approximate 10% decrease in concentration after four days of storage; however, this small decrease could have been attributable to analytical variation alone.
Mephedrone proved to be the most unstable analyte under examination. These data are shown in Table III . When frozen, all three matrices were stable for the 14 day period of the experiment. At 48C, whole blood samples lost approximately 30% of the initial concentration after seven days of storage and more than 50% of the initial concentration after 14 days of storage. Plasma samples decreased in concentration by approximately 10% after four days at 48C and lost a total of 31% of the initial concentration after 14 days of storage. Urine samples remained stable when refrigerated up to 14 days. At room temperature, mephedrone specimens lost a significant portion of the initial concentration, regardless of matrix. In whole blood, more than 30% of the initial concentration was lost after one day and no drug was detectable by the seventh day. In plasma, over 90% of the initial concentration was lost by the fourth day. Urine was more stable, but after 14 days of storage, nearly 60% of the drug had been lost. BZP proved to be relatively stable, with one notable exception, as shown in Table IV . When stored at -208C, whole blood and urine specimens were stable, and plasma showed an apparent 13% decrease in concentration after 14 days. This slight decrease could be attributed to analytical variation. At 48C, each matrix appeared to be stable with concentrations that remained steady. However, at room temperature, although the whole blood and urine samples were stable for 14 days, the plasma sample lost 96% of its concentration within four days and was not detectable after 14 days of storage. The dramatic loss of plasma BZP at room temperature with no decrease in either whole blood or urine samples seems to indicate that BZP is not stable in plasma when samples are stored at elevated temperatures.
The data for TFMPP are shown in Table V . When stored at -208C, TFMPP samples were stable over the examined 14-day period. The same results were obtained when specimens in each matrix were stored at 48C; no loss in concentration was observed. At 228C, urine was stable and demonstrated no apparent concentration decrease. Whole blood showed a slight decrease after one day of storage, losing approximately 16% of its concentration after four days of storage and nearly 35% after seven days. Plasma was stable for one day at 228C but then lost approximately 67% of its concentration after four days and nearly 80% by the end of the experiment.
Conclusions
It was determined that when proper storage conditions are maintained; that is, when specimens were either refrigerated or frozen, MDPV, BZP and TFMPP were stable in all three matrices examined for a period of 14 days. For obvious reasons, storage at room temperature is not recommended and was proven to be detrimental to the stability of each compound. This may be important for cases in which a decedent is severely decomposed or found in an unusually warm environment before sample collection. Mephedrone was stable in all three matrices when the samples remained frozen. At 48C, whole blood specimens showed significant degradation after seven days of storage and more than half of the initial concentration was lost after 14 days. These data suggests a need to freeze samples that screen positive for mephedrone if any type of confirmation analysis is desired.
The piperazine derivatives appeared to be more stable than the synthetic cathinones. This generality may be true only because mephedrone was included in the synthetic cathinone class. The results obtained for mephedrone emphasize the need for further work in this area so that other unstable compounds can be identified and proper precautions taken prior to analysis. 
